Using the specific CBP-beta catenin inhibitor ICG001 and in vitro gene silencing methods, we show that CD133 expression is regulated by CBP-beta-catenin signaling in murine TICs and HCC cells. Here, CREBBP is linked to hepatocellular carcinoma.